Omeros Corp. (OMER)
13.21
-0.80
(-5.71%)
USD |
NASDAQ |
Nov 20, 16:00
13.22
0.00 (0.00%)
After-Hours: 20:00
Omeros Net Income (Quarterly) : -63.82M for Sept. 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | -63.82M |
| June 30, 2026 | 6.637M |
| March 31, 2026 | 51.25M |
| December 31, 2025 | 79.89M |
| September 30, 2025 | -21.24M |
| June 30, 2025 | -25.89M |
| March 31, 2025 | -37.56M |
| December 31, 2024 | -36.54M |
| September 30, 2024 | -37.11M |
| June 30, 2024 | -65.12M |
| March 31, 2024 | -43.85M |
| December 31, 2023 | -39.29M |
| September 30, 2023 | -51.66M |
| June 30, 2023 | -44.29M |
| March 31, 2023 | -39.68M |
| December 31, 2022 | -46.05M |
| September 30, 2022 | -54.79M |
| June 30, 2022 | -41.70M |
| March 31, 2022 | -39.49M |
| December 31, 2021 | -47.31M |
| September 30, 2021 | -44.28M |
| June 30, 2021 | -50.19M |
| March 31, 2021 | -49.77M |
| December 31, 2020 | -39.98M |
| September 30, 2020 | -38.46M |
| Date | Value |
|---|---|
| June 30, 2020 | -33.29M |
| March 31, 2020 | -29.03M |
| December 31, 2019 | -29.22M |
| September 30, 2019 | -16.46M |
| June 30, 2019 | -14.45M |
| March 31, 2019 | -24.34M |
| December 31, 2018 | -23.53M |
| September 30, 2018 | -39.47M |
| June 30, 2018 | -33.70M |
| March 31, 2018 | -30.05M |
| December 31, 2017 | -16.55M |
| September 30, 2017 | -7.482M |
| June 30, 2017 | -14.36M |
| March 31, 2017 | -15.09M |
| December 31, 2016 | -19.63M |
| September 30, 2016 | -13.96M |
| June 30, 2016 | -12.61M |
| March 31, 2016 | -20.54M |
| December 31, 2015 | -19.83M |
| September 30, 2015 | -19.92M |
| June 30, 2015 | -16.68M |
| March 31, 2015 | -18.67M |
| December 31, 2014 | -20.71M |
| September 30, 2014 | -18.33M |
| June 30, 2014 | -17.99M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Eli Lilly & Co. | 6.451B |
| Aytu BioPharma, Inc. | -3.881M |
| Daré Bioscience, Inc. | -3.158M |
| Jaguar Health, Inc. | -5.83M |
| Structure Therapeutics, Inc. | -145.14M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 35.93M |
| Total Expenses (Quarterly) | 99.76M |
| EPS Diluted (Quarterly) | -0.7859 |
| Enterprise Value | 1.180B |
| Gross Profit Margin (Quarterly) | 97.26% |
| Profit Margin (Quarterly) | -177.6% |
| Earnings Yield | 8.47% |
| Normalized Earnings Yield | 14.28 |